About 1 in 30,000 people worldwide has Wilson disease, but it accounts for roughly 2 to 3% of acute liver failure cases. Neurologic symptoms occur in about 40 to 50% of patients and hepatic involvement in about 50 to 60%. Median time to diagnosis is reported at 2.5 years from first symptoms.
Key Takeaways
- 1 in 30,000 people in the general population has Wilson disease
- Approximately 1 in 90 people carry a pathogenic ATP7B variant (are heterozygous carriers)
- Wilson disease accounts for about 1–2% of cases of unexplained liver disease in children
- ATP7B encodes a copper-transporting ATPase; more than 500 different ATP7B variants have been described
- The pathogenic variants in ATP7B are distributed across the gene; Wilson disease is caused by biallelic ATP7B mutations
- Serum ceruloplasmin levels are typically reduced to less than 20 mg/dL in Wilson disease
- Among treated Wilson disease patients, adherence to chelation therapy is critical to prevent relapse and progression
- Penicillamine is dosed typically at 250–500 mg/day in many treatment regimens (with adjustments over time)
- Trientine is dosed typically at 750–1,500 mg/day in many treatment regimens (with adjustments over time)
- Liver enzymes (ALT/AST) decrease after effective chelation therapy in many patients
- Serum ceruloplasmin typically rises toward normal after effective therapy
- Urinary copper excretion decreases with effective chelation
- Penicillamine reduces free copper in plasma and promotes urinary copper excretion
- Trientine is a copper chelator used as an alternative to penicillamine for long-term management
- Zinc therapy is used for maintenance and for presymptomatic disease in some guideline-based strategies
Wilson disease affects about 1 in 30,000 people, and earlier diagnosis with lifelong treatment greatly improves outcomes.
Related reading
01 · Category
Disease Burden30 stats
01
1 in 30,000 people in the general population has Wilson disease
02
Approximately 1 in 90 people carry a pathogenic ATP7B variant (are heterozygous carriers)
03
Wilson disease accounts for about 1–2% of cases of unexplained liver disease in children
04
In patients with acute liver failure, Wilson disease is responsible for about 2–3% of cases
05
A 2019 systematic review estimated global prevalence of Wilson disease at about 3.3 per million people
06
A 2019 systematic review estimated global incidence of Wilson disease at about 0.6 per million person-years
07
The majority of affected individuals present with neurologic or hepatic manifestations, with hepatic disease often more common in younger patients
08
Neurologic symptoms occur in about 40–50% of patients with Wilson disease
09
Hepatic involvement occurs in about 50–60% of patients with Wilson disease
10
Psychiatric symptoms occur in about 20–30% of patients with Wilson disease
11
Kayser–Fleischer rings are found in about 50–60% of patients with Wilson disease
12
Approximately 8–15% of patients with Wilson disease present with acute liver failure
13
Wilson disease is most often diagnosed in the first two decades of life
14
The classic age of onset for neurologic presentations is commonly in late childhood through young adulthood
15
The classic age of onset for hepatic presentations is commonly in childhood or adolescence
16
Untreated Wilson disease is fatal in most patients
17
With effective treatment, prognosis is substantially improved for many patients with Wilson disease
18
About 70% of untreated patients develop severe liver disease or neurologic decline by the time of diagnosis
19
Wilson disease prevalence can be higher in certain regions due to founder effects and consanguinity
20
In some populations, carrier frequency for ATP7B variants is reported as high as about 1 in 60
21
Hepatic manifestations include asymptomatic transaminitis in early stages
22
Cirrhosis may develop in a substantial fraction of patients before diagnosis
23
Reaching a diagnosis before significant organ damage is associated with better outcomes
24
The rate of misdiagnosis can be substantial because Wilson disease is rare and symptoms overlap with other liver and neurodegenerative disorders
25
Delay to diagnosis is often several years after symptom onset
26
Median time to diagnosis in one cohort study of Wilson disease was 2.5 years from first symptoms
27
In a cohort study, 40% of patients had neurologic symptoms at diagnosis
28
In a cohort study, 60% of patients had hepatic symptoms at diagnosis
29
A matched analysis found that patients with Wilson disease have higher all-cause mortality than matched controls
30
Patients with Wilson disease had an increased risk of hospitalization compared with controls in a large registry-based study
Interpretation
Disease Burden Interpretation
Although Wilson disease affects only about 1 in 30,000 people, it explains roughly 2 to 3% of acute liver failure cases and can remain hidden for years, with median time to diagnosis reported at 2.5 years from first symptoms.
More related reading
02 · Category
Genetics & Biomarkers30 stats
01
ATP7B encodes a copper-transporting ATPase; more than 500 different ATP7B variants have been described
02
The pathogenic variants in ATP7B are distributed across the gene; Wilson disease is caused by biallelic ATP7B mutations
03
Serum ceruloplasmin levels are typically reduced to less than 20 mg/dL in Wilson disease
04
Serum ceruloplasmin levels below 5 mg/dL are common in many symptomatic patients
05
Urinary copper excretion is often elevated to more than 100 micrograms per 24 hours
06
Urinary copper excretion of more than 200 micrograms per 24 hours is frequently seen in untreated patients
07
During penicillamine challenge, urinary copper excretion exceeding 1,600 micrograms/24 hours supports Wilson disease
08
Hepatic copper concentration is often elevated above 250 micrograms per gram of dry liver weight in Wilson disease
09
Hepatic copper concentration above 1,600 micrograms per gram of dry liver weight is strongly suggestive
10
Kayser–Fleischer rings reflect corneal copper deposition and are detected by slit-lamp examination
11
Presence of Kayser–Fleischer rings is assigned diagnostic weight in the Leipzig scoring system
12
Leipzig criteria assign a score of 2 points for Kayser–Fleischer rings with compatible ophthalmologic findings
13
Leipzig criteria assign 4 points for a low ceruloplasmin level (<=0.1 g/L; <=10 mg/dL)
14
Leipzig criteria assign 1 point for a ceruloplasmin level in the mildly reduced range
15
Leipzig criteria assign 2 points for an ATP7B genetic diagnosis (biallelic pathogenic variants)
16
Leipzig criteria assign 2 points for a positive penicillamine test with elevated urinary copper
17
Leipzig criteria assign 2 points for hepatic copper concentration above a diagnostic threshold
18
Leipzig scores classify patients as 'unlikely' at total score <4, 'possible' at 4–3, 'probable' at 4–6, and 'highly probable' at ≥7 (thresholding varies by interpretation)
19
In a study of Leipzig scoring, a score ≥7 yielded high diagnostic accuracy for Wilson disease
20
A meta-analysis reported that genetic testing for ATP7B mutations can confirm Wilson disease in a substantial proportion of clinically suspected cases
21
The common ATP7B variant p.H1069Q is present at higher frequency in some European populations
22
In a population genetics study, p.H1069Q accounted for about 20–30% of mutant alleles in selected cohorts
23
A frequent pathogenic variant is p.R778L (historically described as p.R778L / c.2335C>T) in some populations
24
In a reported cohort, p.R778L contributed to a measurable fraction of ATP7B mutations
25
Approximately 40% of Wilson disease cases are compound heterozygotes rather than homozygotes in many cohorts
26
Some cohorts show that homozygous ATP7B mutations account for about 10–20% of cases
27
Most diagnostic frameworks consider biallelic ATP7B mutations as a strong indicator of Wilson disease
28
Hemolysis due to copper toxicity can present as elevated bilirubin and anemia
29
Coombs-negative hemolytic anemia occurs in a subset of Wilson disease patients
30
Ceruloplasmin is produced by the liver; low levels reflect impaired copper incorporation into ceruloplasmin
Interpretation
Genetics & Biomarkers Interpretation
Overall, the data show that classical Wilson disease biochemistry is often striking, with ceruloplasmin typically below 20 mg/dL, urinary copper frequently above 200 μg/24 hours in untreated patients, and Leipzig scoring reaching highly probable levels at totals of 7 or more.
More related reading
03 · Category
Diagnosis & Care30 stats
01
Among treated Wilson disease patients, adherence to chelation therapy is critical to prevent relapse and progression
02
Penicillamine is dosed typically at 250–500 mg/day in many treatment regimens (with adjustments over time)
03
Trientine is dosed typically at 750–1,500 mg/day in many treatment regimens (with adjustments over time)
04
Zinc therapy for Wilson disease is commonly prescribed at 75 mg of elemental zinc 3 times daily (total 225 mg/day) in some regimens
05
Zinc monotherapy is generally reserved for asymptomatic patients and maintenance rather than acute presentations
06
Liver transplantation is indicated for fulminant hepatic failure or end-stage liver disease not responding to medical therapy
07
In a review of transplant outcomes, 1-year survival after liver transplantation for Wilson disease is about 85–90%
08
In a review of transplant outcomes, 5-year survival after liver transplantation for Wilson disease is about 75–85%
09
Long-term outcomes depend on neurologic status at transplantation
10
Chelation therapy can normalize liver enzymes and reduce hepatic copper over time
11
Penicillamine therapy is associated with adverse effects including rash, bone marrow suppression, and nephrotoxicity in a minority of patients
12
In clinical practice guidelines, trientine is an alternative chelator with different adverse-effect profile compared with penicillamine
13
Zinc adverse effects include GI symptoms and copper deficiency; serum copper may need monitoring
14
Patients treated with chelators require monitoring of blood counts, liver function tests, and urinary copper (or clinical markers)
15
Monitoring generally includes liver biochemistry every 3 months during stabilization and periodically thereafter
16
The EASL clinical practice guidelines recommend lifelong treatment and ongoing monitoring
17
EASL guidelines specify that maintenance dosing aims for low free copper burden and stable biochemical response
18
EASL guidelines recommend zinc for maintenance therapy after initial chelation
19
EASL guidelines recommend penicillamine for initial treatment in neurologic Wilson disease in some circumstances
20
EASL guidelines recommend trientine as an alternative initial therapy
21
After chelation, 24-hour urinary copper output typically decreases to a monitoring target range under effective therapy
22
In a clinical response definition, effective treatment is associated with reduced urinary copper excretion (measured over 24 hours)
23
In a study of maintenance therapy, urinary copper excretion decreased substantially from baseline after chelation and transitioned toward maintenance levels
24
D-penicillamine (penicillamine) was approved for Wilson disease use; dosing in trials and guidelines varies by age and severity
25
A randomized controlled trial comparing different chelation strategies is limited; most evidence comes from cohort studies and guideline synthesis
26
In a long-term cohort study, neurologic improvement occurred in a substantial fraction of patients after chelation
27
In that cohort, about 50% of patients with neurologic symptoms improved on therapy
28
In the same cohort, deterioration despite therapy was reported in a minority of neurologic cases
29
Adherence is monitored through clinical follow-up and biochemical response rather than direct drug level measurement in routine practice
30
Family screening is recommended for first-degree relatives once a diagnosis is made
Interpretation
Diagnosis & Care Interpretation
Across cohorts and guideline-based practice, about half of patients with neurologic Wilson disease improved after chelation while long-term liver transplant outcomes remained strong with roughly 85 to 90% survival at 1 year and 75 to 85% at 5 years, underscoring that treatment success depends heavily on early effective management and sustained monitoring.
More related reading
04 · Category
Treatment Effectiveness30 stats
01
Liver enzymes (ALT/AST) decrease after effective chelation therapy in many patients
02
Serum ceruloplasmin typically rises toward normal after effective therapy
03
Urinary copper excretion decreases with effective chelation
04
The therapeutic effect of zinc includes induction of metallothionein in enterocytes and reduced copper absorption
05
With zinc therapy, urinary copper may decrease substantially in maintenance patients
06
A study reported that after zinc therapy, 24-hour urinary copper excretion fell by roughly 50% from baseline
07
In clinical cohorts, biochemical normalization rates for liver disease can be high after chelation
08
One cohort reported normalization of liver enzymes in about 70–80% of treated patients over follow-up
09
In that cohort, urinary copper decreased markedly in the majority (around 80%) of patients
10
In patients treated early, neurological outcomes are generally better than for those with delayed diagnosis
11
In one observational study, patients treated within 3 months of symptom onset had better neurologic improvement rates (about 60%) than those treated later (about 30%)
12
After successful liver transplantation, hepatic copper burden is effectively eliminated because the transplanted liver restores normal copper metabolism
13
In transplanted patients, survival at 5 years is reported around 80% in aggregate analyses
14
In aggregate analyses, 1-year survival after liver transplantation is reported around 88%
15
Neurologic symptoms may take longer to improve or may partially persist after transplantation
16
A study on transplant outcomes reported neurologic improvement in roughly one-third of patients
17
Relapse risk exists if therapy is stopped; lifelong therapy is recommended to prevent copper re-accumulation
18
In clinical guidance, discontinuation of chelation/zinc leads to copper recurrence in most cases
19
Adverse effects occur with chelators; penicillamine adverse reactions are reported in a meaningful minority of patients (reported ranges vary by study)
20
Trientine is often used when penicillamine is not tolerated; comparative adverse-event profiles are discussed in guidelines
21
In observational data, treatment-related adverse events were less frequent with trientine than with penicillamine in some cohorts
22
One cohort reported penicillamine discontinuation due to adverse events in about 10–20% of patients
23
In the same context, trientine discontinuation due to adverse events was reported at about 5–10%
24
Zinc maintenance therapy was associated with fewer systemic adverse effects than chelators in comparative reports
25
In a study, GI intolerance was among the more common zinc-related adverse events, reported in a minority of patients
26
In that zinc therapy study, about 15% experienced clinically relevant GI symptoms leading to dose adjustment
27
In long-term cohorts, treatment continuation is high when patients are monitored and educated; one study reported ongoing therapy in over 80% at follow-up
28
In that follow-up study, median follow-up duration was about 5 years
29
MRI brain abnormalities in Wilson disease can show basal ganglia involvement patterns; imaging abnormalities improve variably with therapy
30
In a longitudinal imaging study, MRI signal changes improved in about 40–60% of treated patients over follow-up
Interpretation
Treatment Effectiveness Interpretation
Across observational data, starting therapy early appears to pay off, with neurologic improvement reported around 60% when treatment begins within 3 months of symptom onset versus about 30% when started later, while biochemical liver normalization occurs in roughly 70 to 80% of chelated patients.
More related reading
05 · Category
Industry Trends21 stats
01
Penicillamine reduces free copper in plasma and promotes urinary copper excretion
02
Trientine is a copper chelator used as an alternative to penicillamine for long-term management
03
Zinc therapy is used for maintenance and for presymptomatic disease in some guideline-based strategies
04
EASL guidelines were published in 2012 and updated practice for diagnosis and treatment of Wilson disease in Europe
05
A subsequent EASL guideline update emphasized revised recommendations for treatment targets and monitoring (2017 publication)
06
Leipzig score was originally described in 2003 to aid diagnosis of Wilson disease
07
The 2003 Leipzig diagnostic scoring system provides a standardized approach integrating ophthalmology, biochemical tests, and genetics
08
Universal screening programs for Wilson disease are not standard in most countries; diagnosis is typically case-based and triggered by symptoms or family history
09
In European countries, awareness campaigns and genetic testing expansion have increased diagnosis rates over time (observed in registry data)
10
In a U.S. administrative database study, prevalence increased over the study window, consistent with improved detection
11
In that U.S. study, estimated Wilson disease prevalence reached 3.6 per 100,000 persons by the end of the period
12
In that U.S. study, estimated incidence was 0.3 per 100,000 person-years
13
A UK-based review found that Wilson disease is among rare diseases frequently diagnosed after symptom onset, with delays contributing to higher morbidity
14
In that review, median time to diagnosis was 2.5 years
15
The European reference network for rare liver diseases (ERN RARE-LIVER) lists Wilson disease as a key condition for specialist care
16
In clinical trials and publications, 24-hour urinary copper is used as a key biomarker to monitor copper chelation response
17
Hepatic copper concentration (micrograms per gram dry weight) is used in diagnostic evaluation where liver biopsy is performed
18
Penicillamine, trientine, and zinc are the core pharmacologic categories used in standard care for Wilson disease
19
Clinical use of genetic testing for ATP7B has expanded substantially since early 2000s guidelines and the Leipzig score were published
20
Wilson disease is a primary target condition in specialty hepatology and neurology clinical pathways for rare inherited liver disorders
21
A 2019 systematic review reported diagnostic criteria heterogeneity but supported higher accuracy when combining clinical, biochemical, and genetic data
Interpretation
Industry Trends Interpretation
Across studies, Wilson disease diagnosis is improving but still catching patients late, with median time to diagnosis around 2.5 years while U.S. estimates show prevalence rising to 3.6 per 100,000 by the end of the study period and incidence at 0.3 per 100,000 person-years.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Nathan Caldwell. (2026, February 13). Wilsons Disease Statistics. Gitnux. https://gitnux.org/wilsons-disease-statistics
MLA
Nathan Caldwell. "Wilsons Disease Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/wilsons-disease-statistics.
Chicago
Nathan Caldwell. 2026. "Wilsons Disease Statistics." Gitnux. https://gitnux.org/wilsons-disease-statistics.
Sources & references
22 datasets cited across this report · attribution is report-level
+19 additional datasets cited (not shown individually)